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Introduction
Quantification of coronary artery calcium by computed 
tomography represents a reliable estimate of atheroscle-
rotic plaque burden and the prognostic value of the coro-
nary artery calcium score (CACS) is well established [1, 
2]. Recently, coronary computed tomographic angiography 
(CCTA) has emerged as an important imaging tool to detect 
the presence and extent of coronary artery disease (CAD) 
[3, 4]. Several large prospective trials have demonstrated 
the prognostic value of CCTA, with a high negative pre-
dictive value for the occurrence of major adverse cardiac 
events (MACE) [5–11]. Overestimation of the severity of 
CAD in patients with a high pre-test probability is, however, 
a known limitation of CCTA [12, 13]. Thus, the appropriate 
use criteria advise to only use CCTA in patients with low or 
intermediate pre-test probability [14]. The aim of this study 
was therefore to evaluate the independent prognostic value 
of CCTA and CACS in a routine clinical cohort of symp-
tomatic patients with low or intermediate pre-test probabil-
ity, in which CCTA is appropriate.
Methods
Population
From 13 December 2011 to 26 August 2014 all patients with 
chest pain with low or intermediate pre-test probability of 
CAD, referred for CCTA from the outpatient clinic after a 
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Abstract
Background Limited studies report on the additional prog-
nostic value of coronary computed tomography angiogra-
phy (CCTA) and the coronary artery calcium score (CACS).
Methods For a median of 637 days, 1551 outpatients with 
chest pain, without known coronary artery disease (CAD) 
and low or intermediate pre-test probability of CAD, were 
followed for major adverse cardiac events (MACE), defined 
as death, myocardial infarction or late revascularisation. 
Cox proportional hazard regression was used to evaluate the 
independent prognostic value of CCTA and CACS.
Results MACE occurred in 23 patients (1.5 %): death (3, 
0.2 %), myocardial infarction (4, 0.3 %) and late revascu-
larisation (16, 1.3 %). Multivariate analysis showed an in-
dependent prognostic value of CCTA (p < 0.001), CACS 
of 100–400 (p = 0.035) and CACS of > 400 (p = 0.021). 
CCTA showed obstructive CAD in 3.1 % of patients with 
CACS = 0. No events occurred in patients with CACS = 0 
without obstructive CAD at CCTA, whereas 2/23 patients 
(9 %) with CACS = 0 with obstructive CAD had a MACE.
Conclusions Our study shows that both CCTA and higher 
CACS categories have independent prognostic value in 
chest pain patients with low to intermediate pre-test prob-
ability of obstructive CAD, in which CCTA is appropri-
ate. Furthermore a non-negligible amount of patients with 
CACS = 0 have obstructive CAD at CCTA. CCTA can be 
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Definition of CAD
Obstructive CAD was defined as a lumen stenosis in any 
of the large vessels of > 50 %, either the left main artery, 
left anterior descending artery, circumflex artery or right 
coronary artery. Normal coronary arteries were defined as 
CACS = 0 and no coronary plaques. Non-obstructive CAD 
was defined as CACS > 0 and/or any plaque that did not 
meet the criteria for obstructive CAD.
Statistical analysis
Statistical analysis was performed using SPSS software, 
version 22.0.0 (SPSS Inc, Chicago, Illinois). Continuous 
variables are presented as mean ± SD and categorical vari-
ables as frequencies with percentages. Continuous variables 
were tested for normal distribution.
Kaplan-Meier analysis was used to assess MACE-free 
survival stratified by CACS and CCTA results. Univari-
ate and subsequent multivariate Cox proportional hazard 
regression were used to evaluate the independent prog-
nostic value of CACS and CCTA beyond clinical risk fac-
tors. The multivariate Cox regression was done in stepwise 
fashion according to the backwards approach, with p < 0.10 
as threshold for removal of variables. Clinical risk factors 
included in the univariate analysis were male gender, age, 
diabetes, smoking, hyperlipidaemia, hypertension, and fam-
ily history of CAD. Selection of variables for entry in the 
multivariable Cox proportional hazard regression was based 
on univariate analysis with a threshold of p < 0.10.
Results
Population
A total of 1560 patients were initially included in the data-
base for follow-up. Follow-up could be obtained in 99.4 % 
of the patients. Nine patients emigrated to a foreign coun-
try and were lost to follow-up. The total number of studied 
patients was 1551. An overview of the baseline characteris-
tics is shown in Table 1.
CCTA data
CACS, CCTA results and radiation dose are summarised in 
Table 2. Two patients with left main CAD on CCTA also 
had three-vessel disease.
Follow-up
The cohort was followed for a median of 637 days. MACE 
occurred in 23 patients during follow-up. Three (0.2 %) 
diagnostic work up, were prospectively included. None of 
the patients had a prior history of CAD. The pre-test prob-
ability was calculated using the Duke Clinical Score [15]. A 
pre-test probability < 15 % was defined as low and 15–85 % 
was defined as intermediate, according to the ESC guide-
lines [3].
Baseline characteristics including age, gender, and car-
diovascular risk factors were prospectively entered in the 
database. All patients gave written informed consent for 
usage of their data.
Follow-up
Patients were followed for MACE, defined as all-cause 
mortality, myocardial infarction or revascularisation (either 
CABG or PCI). A 60-day landmark was used to differenti-
ate between CCTA-driven invasive coronary angiography 
and late revascularisation, which is considered to be indica-
tive for the prognostic value of CCTA. Patients with referral 
for invasive coronary angiography in the outpatient setting 
within 60 days after CCTA and subsequent revascularisa-
tion were considered to be CCTA-driven and not MACE. 
All other revascularisations within follow-up were consid-
ered to be MACE. Information on myocardial infarction and 
revascularisation was obtained from the electronic medical 
records. Information on mortality was obtained from the 
municipal personal records database.
CCTA preparation, acquisition and analysis
Patient preparation, image acquisition, and image analysis 
were performed as previously described [16] and as briefly 
described below.
All scans were performed with a 2 × 64–slice flying focal 
spot, effectively 2 × 128–slice (Somatom Definition Flash; 
Siemens Medical Systems, Erlangen, Germany) and were 
evaluated by a Certification Board of Cardiovascular Com-
puted Tomography accredited nuclear medicine physician 
and a cardiologist experienced in the interpretation of CCTA 
in consensus. In case of disagreement a third opinion was 
decisive.
Radiation dose
The radiation dose delivered was generated automati-
cally by the scanner software and represented as dose 
length product. The effective dose was calculated by 
multiplying the dose length product with the k-factor of 
0.014 mSv × (mGy × cm)−1, which is generally used in car-
diac CT studies.
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worse in CACS 0 patients with obstructive CAD, log-rank 
p-value < 0.001.
Independent prognostic value of CACS and CCTA
The evaluation of the predictive value of CACS and CCTA 
by univariate and multivariate Cox proportional hazard 
regression is shown in Table 3. By univariate analysis, 
increased risk of MACE was observed with increasing 
CACS (p-value < 0.001). Furthermore, obstructive CAD at 
CCTA was associated with a 13-fold increase in unadjusted 
risk of MACE. Of all clinical risk factors, male gender and 
hypertension had a p-value of < 0.10 and were subsequently 
included in the multivariate analysis.
In the multivariate model, obstructive disease on CCTA 
was independently associated with increased risk of MACE 
(p < 0.001). Furthermore, CACS of 100–400 (p = 0.035) and 
CACS of > 400 (0.021) were independent predictors for the 
occurrence of MACE, whereas a CACS of 0–100 (p = 0.29) 
had no independent predictive value for the occurrence of 
MACE.
Discussion
Our study shows that in a routine clinical cohort of patients 
referred from the outpatient clinic with chest pain with low 
to intermediate pre-test probability of obstructive CAD, the 
patients died, 4 (0.3 %) patients had a myocardial infarction, 
and 20 (1.3 %) patients had non-CCTA-driven revasculari-
sations. Four patients (0.3 %) were acute revascularisations 
in myocardial infarction and 16 (1.0 %) were late revascu-
larisations, referred beyond 60 days after CCTA because of 
ongoing symptoms.
Figure 1 shows the MACE-free survival estimates strati-
fied by CACS and CCTA. Both increase in CACS and pres-
ence of obstructive CAD at CCTA were associated with 
decreased MACE-free survival (log-rank p-value < 0.01).
MACE occurred in no patients with normal coronary 
arteries at CCTA, in 1.0 % of patients with non-obstruc-
tive CAD at CCTA and in 7.5 % of patients with obstruc-
tive CAD at CCTA. During follow-up, MACE occurred in 
0.3 % of patients with CACS = 0, in 1.0 % of patients with 
CACS 1–100, in 4.2 % with CACS 101–400 and in 7.1 % 
with CACS > 400.
Of all 739 patients with CACS = 0, 23 (3.1 %) had 
obstructive CAD at CCTA and 62 (8.4 %) had non-obstruc-
tive CAD at CCTA. No events occurred in patients with 
CACS = 0 and no obstructive CAD at CCTA, whereas 
2/23 patients (9 %) with CACS = 0 and obstructive CAD at 
CCTA had a MACE during follow-up: late revascularisa-
tion in both cases. MACE-free survival was significantly 
Table 1 Baseline characteristics
Variable Total (n = 1551)
Demographics
Age 58.0 ± 10.2
Women 968 (62.4 %)
Body mass index 26.6 ± 4.5
Diabetes 121 (7.8 %)
Hba1c (n = 53)a 6.8 ± 1.6
Hypertension 464 (29.9 %)
Hyperlipidaemia 393 (25.3 %)
Family history of CADb 731 (47.2 %)
Smoking 277 (17.9 %)
eGFR < 60 44 (2.8 %)
Duke clinical score
– Low (< 15 %) 527 (34.0 %)
– Low-intermediate (15–50 %) 760 (49.0 %)
– High-intermediate (50–85 %) 264 (17.0 %)
Baseline medication use
Aspirin 499 (32.2 %)
Statin 531 (34.2 %)
Beta-blocker 604 (38.9 %)
ACE-i/ARB 390 (25.1 %)
Calcium channel blocker 96 (6.2 %)
Nitrate 49 (3.2 %)
Acenocoumarol 38 (2.5 %)
eGFR estimated glomerular filtration rate, ACE-I/ARB ACE-
inhibitor/angiotensin receptor blocker.
aHba1C was documented in only 53 patients.
bIn 2 patients family history of CAD was missing.
Table 2 CCTA data
Variable Total (n = 1551)
Coronary artery calcium score
0 739 (47.6 %)
0.1–100 498 (32.1 %)
100–400 215 (13.9 %)
> 400 99 (6.5 %)
CCTA results
Normal coronary arteries 654 (42.2 %)
Non-obstructive CAD 683 (44.0 %)
Obstructive CAD (> 50 %) 214 (13.8 %)
1-vessel 164 (10.6 %)
2-vessel 34 (2.2 %)
3-vessel 13 (0.8 %)
Left main 4 (0.3 %)
High-risk lesionsa 48 (3.1 %)
Radiation dose
All patients (n = 1551) 2.4 ± 2.0 mSv
High-pitch FLASH scans (n = 1130) 1.6 ± 0.7 mSv
Prospectively triggered scans (n = 386) 4.5 ± 2.5 mSv
Retrospectively triggered scans (n = 35) 6.5 ± 2.7 mSv
CCTA coronary computed tomography angiography, CAD coronary 
artery disease, PTP pre-test probability.
ahigh-risk lesions were defined as left main, three-vessel and/or 
proximal left anterior descending disease.
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Furthermore, our study shows that although overall 
prognosis in this clinical cohort was excellent, presence of 
obstructive CAD on CCTA had an independent prognostic 
value. CACS of 0–100 did not show independent prognos-
tic value of CCTA; however CACS 100–400 and > 400 did 
show independent prognostic value.
Prognostic value of CACS and CCTA
The prognostic value of CACS has been previously demon-
strated in large meta-analyses [1, 2]. A recently published 
large multicentre international cohort by Al-Mallah et al. 
reported a gradual increase in event rates in patients with 
CACS = 0, CACS 1–100, 100–399 and > 400, with compa-
rable event rates to our study [10].
Multiple studies have previously reported on the prog-
nostic value of CCTA for the occurrence of adverse events 
[6–11]. Our study results are in line with a recently pub-
lished meta-analysis of 41,960 patients which reported that 
normal coronary arteries at CCTA are associated with a very 
low annual event rate of < 0.5 % and that obstructive CAD 
at CCTA is associated with higher event rates of 12.5 % 
[17]. The slightly lower event rate in patients with obstruc-
tive CAD at CCTA in our study might be explained by the 
fact that no patients with a high pre-test probability were 
included.
CACS of 0
Our study, in accordance with prior studies, showed 
an excellent prognosis of symptomatic patients with 
CACS = 0, with an event rate < 1 % within 2 years of fol-
prognosis of a CACS of 0 is excellent, with MACE during 
follow-up in only 0.3 % of patients. However, a non-neg-
ligible amount of patients with CACS = 0 had obstructive 
CAD (3 %). Presence of CAD in patients with CACS = 0 
was associated with worse prognosis.
Table 3 Univariate and multivariate Cox regression of risk factors, 
CACS and CCTA
Variable HR 95 % CI P-value
Univariate analysis
Male gender 2.18 0.96–4.97 0.064a
Age 1.02 0.98–1.07 0.26
Diabetes mellitus 1.15 0.55–2.43 0.71
Hypertension 2.31 1.02–5.24 0.045a
Family history 1.76 0.76–4.07 0.19
Smoking 0.71 0.21–2.40 0.58
Hyperlipidaemia 1.97 0.85–4.55 0.11
CACS
CACS = 0 Reference Reference -
CACS 0–100 3.71 0.72–19.12 0.12
CACS 100–400 15.82 3.42–72.23 < 0.001a
CACS > 400 26.81 5.57–129.09 < 0.001a
Obstructive CAD at CCTA 15.28 6.28–37.14 < 0.001a
Multivariate analysis
Obstructive CAD at CCTA 7.03 2.57–19.22 < 0.001
CACS
CACS = 0 Reference Reference -
CACS 0–100 2.46 0.46–13.14 0.29
CACS 100–400 5.97 1.14–31.31 0.035
CACS > 400 7.72 1.37–43.55 0.021
CACS coronary artery calcium score, CCTA coronary computed 
tomography angiography, HR hazard ratio
avariables with p < 0.10 on univariate analysis
Fig. 1 Kaplan-Meier curves of MACE-free survival stratified by CACS (a) and CCTA results (b)
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reported independent prognostic value of both CCTA and 
CACS, with prognostic value across all categories of CACS 
[24]. In our study CACS had independent prognostic value, 
although only in the categories CACS 100–400 and > 400, 
whereas CACS 0–100 did not have prognostic value. This 
may be partly explained by the relatively low event rate and 
the lower risk population compared with the study popu-
lation of Chaikriangkrai et al. The independent prognos-
tic power of higher categories of CACS together with the 
fact that severe coronary calcification is associated with 
decreased diagnostic accuracy of CCTA, [27] support the 
use of CACS with CCTA as compared with CCTA only.
Clinical implications
The recently published PROMISE trial investigated symp-
tomatic patients with suspected CAD who require non-
invasive testing and reported no difference in outcome 
between an initial strategy of CCTA and functional testing 
[28]. However, questions were raised about the safety of 
the CCTA strategy because of a relatively high radiation 
dose. The reported radiation dose in previous reports on the 
prognostic value of CCTA ranged from 3 to 18 mSv [5, 23, 
28]. With the use of a high-resolution (2 × 128) scanner and 
predominantly a flash or prospective scanning protocol, we 
were able to perform a complete CCTA (calcium score and 
angiography) with an excellent prognostic value and a sub-
stantially lower radiation burden of 2.4 ± 2.0 mSv. Although 
the event rate was relatively low in our study, this further 
supports the use of an initial CCTA strategy in patients with 
low to intermediate pre-test probability of obstructive CAD.
Study limitations
The single-centre design of our study allows the evaluation 
of prognosis in a ‘real world’ clinical setting. However, our 
results may not be applied to all outpatient chest pain popu-
lations, i.e. asymptomatic or high-risk patients.
As in previous studies, a 60-day landmark was used to 
differentiate between CCTA-driven invasive coronary angi-
ography and long-term revascularisation, which is consid-
ered to be indicative for the prognostic value of CCTA [6]. 
Recently, several studies have reported that CCTA has a sig-
nificant effect on downstream patient management [29, 30]. 
In our study 93 (6.0 %) patients underwent CCTA-guided 
revascularisation (referral for PCI/CABG within 60 days 
of CCTA). Since the aim of our study was to evaluate the 
prognostic value of CCTA in a routine clinical cohort, these 
patients were not excluded for analysis. However, outcome 
of the patients might have been confounded by CCTA-
guided management changes.
low-up [10, 18–20]. Because of higher costs, the need to 
administer intravenous contrast and the higher radiation 
burden of CCTA, it remains the subject of discussion 
whether one should proceed with CCTA after CACS = 0 in 
all patients, given the excellent prognosis of these patients. 
The ESC guidelines on stable CAD do not recommend the 
use of CACS to identify individuals at risk [3]. However, a 
recent update of the American College of Cardiology and 
the American Heart Association stated that the exclusion 
of coronary calcium by CACS may be reasonable before 
considering further testing in symptomatic patients with 
low to intermediate pre-test probability [21]. Our study 
confirms findings of recent studies that in symptom-
atic patients with CACS = 0, a non-negligible 1.4–4.5 % 
have evidence of obstructive CAD at CCTA [10, 18, 19]. 
No events occurred during follow-up in patients with 
CACS = 0 and no obstructive CAD at CCTA in our study 
and obstructive CAD at CCTA was significantly associated 
with a worse prognosis. CCTA was thus able to accurately 
identify those with CACS = 0 at risk for future events. 
Performing CCTA after CACS = 0 may still be advisable 
in symptomatic patients with low to intermediate pre-test 
probability to identify those at risk for future events.
Independent prognostic value of CCTA
Several studies have been published on the independent 
prognostic value of CCTA to CACS. Cho et al. reported that 
in 7590 studied asymptomatic patients, CCTA did not have 
prognostic value independent of CACS [22]. Other studies 
have shown that in predominantly symptomatic patients, 
CCTA has added prognostic value to CACS and clinical risk 
factors [6, 10, 23]. These studies, however, differ in study 
populations from our study. Hadamitzky et al. reported on 
the added prognostic value of CCTA to CACS in a popula-
tion of both symptomatic and asymptomatic patients [23]. 
The single-centre study by Hou et al. included a substan-
tial number of asymptomatic patients and patients with high 
pre-test probability [6]. Both Al-Mallah et al. and Van Werk-
hoven et al. studied solely symptomatic patients; 10 % of 
their population, however, had a high pre-test probability [8, 
10]. The appropriate use criteria advise to only use CCTA 
with a low or intermediate pre-test probability [14]. While 
our findings are mainly of a confirmatory nature, our study 
does provide some additional information about the inde-
pendent prognostic value of CCTA to CACS in a Dutch rou-
tine clinical cohort of symptomatic patients, in which CCTA 
is appropriate [14].
Independent prognostic value of CACS
Data on the independent prognostic value of CACS in the 
CCTA era are limited [24–26]. Chaikriangkrai et al. recently 
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 8. Werkhoven JM van, Schuijf JD, Gaemperli O, et al. Incremental 
prognostic value of multi-slice computed tomography coronary 
angiography over coronary artery calcium scoring in patients with 
suspected coronary artery disease. Eur Heart J. 2009;30:2622–9.
 9. Graaf FR de, Velzen JE van, Boer SM de, et al. Non-invasive 
computed tomography coronary angiography as a gatekeeper 
for invasive coronary angiography. Int J Cardiovasc Imaging. 
2013;29:221–8.
10. Al-Mallah MH, Qureshi W, Lin FY, et al. Does coronary CT angi-
ography improve risk stratification over coronary calcium scoring 
in symptomatic patients with suspected coronary artery disease? 
Results from the prospective multicenter international CONFIRM 
registry. Eur Heart J Cardiovasc Imaging. 2014;15:267–74.
11. Werkhoven JM van, Gaemperli O, Schuijf JD, et al. Multislice 
computed tomography coronary angiography for risk stratifica-
tion in patients with an intermediate pretest likelihood. Heart. 
2009;95:1607–11.
12. Budoff MJ, Dowe D, Jollis JG, et al. Diagnostic performance of 
64-multidetector row coronary computed tomographic angiog-
raphy for evaluation of coronary artery stenosis in individuals 
without known coronary artery disease: results from the pro-
spective multicenter ACCURACY (Assessment by Coronary 
Computed Tomographic Angiography of Individuals Undergo-
ing Invasive Coronary Angiography) trial. J Am Coll Cardiol. 
2008;52:1724–32.
13. Meijboom WB, Mieghem CA van, Mollet NR, et al. 64-Slice Com-
puted Tomography Coronary Angiography in Patients with High, 
Intermediate, Or Low Pretest Probability of Significant Coronary 
Artery Disease. J Am Coll Cardiol. 2007;50:1469–75.
14. Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/
AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use cri-
teria for cardiac computed tomography. A report of the American 
College of Cardiology Foundation Appropriate Use Criteria Task 
Force, the Society of Cardiovascular Computed Tomography, the 
American College of Radiology, the American Heart Association, 
the American Society of Echocardiography, the American Society 
of Nuclear Cardiology, the North American Society for Cardiovas-
cular Imaging, the Society for Cardiovascular Angiography and 
Interventions, and the Society for Cardiovascular Magnetic Reso-
nance. J Am Coll Cardiol. 2010;56:1864–94.
15. Bayliss J. Duke Clinical Score: prediction of Coronary Heart Dis-
ease in a Patient with Chest Pain. 2009. http://www.zunis.org/
Duke%20Chest%20Pain%20-%20CAD%20Predictor.htm.
16. Krul MM, Bogaard K, Knol RJ, et al. Coronary artery disease in 
patients with atypical chest pain with and without diabetes mel-
litus assessed with coronary CT angiography. BMJ Open Diabetes 
Res Care. 2014;2:e000004.
17. Habib PJ, Green J, Butterfield RC, et al. Association of cardiac 
events with coronary artery disease detected by 64-slice or greater 
coronary CT angiography: a systematic review and meta-analysis. 
Int J Cardiol. 2013;169:112–20.
18. Villines TC, Hulten EA, Shaw LJ, et al. Prevalence and severity 
of coronary artery disease and adverse events among symptomatic 
patients with coronary artery calcification scores of zero undergo-
ing coronary computed tomography angiography: results from the 
CONFIRM (Coronary CT Angiography Evaluation for Clinical 
Outcomes: an International Multicenter) registry. J Am Coll Car-
diol. 2011;58:2533–40.
19. Kim YJ, Hur J, Lee HJ, et al. Meaning of zero coronary calcium 
score in symptomatic patients referred for coronary computed 
tomographic angiography. Eur Heart J Cardiovasc Imaging. 
2012;13:776–85.
Conclusion
This study shows that both CCTA and CACS of 100–400 
and > 400 have an independent prognostic value for the 
occurrence of MACE in a routine clinical cohort of patients 
presenting to the outpatient clinic with atypical chest pain 
with low to intermediate pre-test probability of obstruc-
tive CAD, in which CCTA is appropriate. Furthermore our 
study shows that a non-negligible amount of patients with 
CACS = 0 have obstructive CAD at CCTA. CCTA can be 
used in patients with CACS = 0 to identify those at risk for 
MACE.
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